RNF213 and familial isolated congenital asplenia: An ongoing clinical trial is investigating whether there is a proportion of ICAS-diagnosed patients who have MMD instead through follow-up angiography and systematic testing for genetic biomarkers, elucidating whether RNF213 variants may have a future role in distinguishing between ICAS and MMD [90].